|
1
|
Ricchi P, Zarrilli R, Di Palma A and
Acquaviva AM: Nonsteroidal anti-inflammatory drugs in colorectal
cancer: From prevention to therapy. Br J Cancer. 88:803–807. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tsukuma H, Ajiki W and Oshima A: Cancer
incidence in Japan. Gan To Kagaku Ryoho. 31:840–846. 2004.In
Japanese. PubMed/NCBI
|
|
3
|
Matsuda T, Marugame T, Kamo K, Katanoda K,
Ajiki W and Sobue T; Japan Cancer Surveillance Research Group.
Cancer incidence and incidence rates in Japan in 2004: Based on
data from 14 population-based cancer registries in the Monitoring
of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol.
40:1192–1200. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kobayashi H, Mochizuki H, Sugihara K,
Morita T, Kotake K, Teramoto T, Kameoka S, Saito Y, Takahashi K,
Hase K, et al: Characteristics of recurrence and surveillance tools
after curative resection for colorectal cancer: A multicenter
study. Surgery. 141:67–75. 2007. View Article : Google Scholar
|
|
5
|
Weitz J, Koch M, Debus J, Höhler T, Galle
PR and Büchler MW: Colorectal cancer. Lancet. 365:153–165. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ross JS, Torres-Mora J, Wagle N, Jennings
TA and Jones DM: Biomarker-based prediction of response to therapy
for colorectal cancer: Current perspective. Am J Clin Pathol.
134:478–490. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Y, Jatkoe T, Zhang Y, Mutch MG,
Talantov D, Jiang J, McLeod HL and Atkins D: Gene expression
profiles and molecular markers to predict recurrence of Dukes' B
colon cancer. J Clin Oncol. 22:1564–1571. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shih W, Chetty R and Tsao MS: Expression
profiling by microarrays in colorectal cancer (Review). Oncol Rep.
13:517–524. 2005.PubMed/NCBI
|
|
9
|
Nannini M, Pantaleo MA, Maleddu A, Astolfi
A, Formica S and Biasco G: Gene expression profiling in colorectal
cancer using microarray technologies: Results and perspectives.
Cancer Treat Rev. 35:201–209. 2009. View Article : Google Scholar
|
|
10
|
Aragane H, Sakakura C, Nakanishi M,
Yasuoka R, Fujita Y, Taniguchi H, Hagiwara A, Yamaguchi T, Abe T,
Inazawa J, et al: Chromosomal aberrations in colorectal cancers and
liver metastases analyzed by comparative genomic hybridization. Int
J Cancer. 94:623–629. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kurashina K, Yamashita Y, Ueno T, Koinuma
K, Ohashi J, Horie H, Miyakura Y, Hamada T, Haruta H, Hatanaka H,
et al: Chromosome copy number analysis in screening for
prognosis-related genomic regions in colorectal carcinoma. Cancer
Sci. 99:1835–1840. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakao M, Kawauchi S, Furuya T, Uchiyama T,
Adachi J, Okada T, Ikemoto K, Oga A and Sasaki K: Identification of
DNA copy number aberrations associated with metastases of
colorectal cancer using array CGH profiles. Cancer Genet Cytogenet.
188:70–76. 2009. View Article : Google Scholar
|
|
13
|
Yamamoto S, Midorikawa Y, Morikawa T,
Nishimura Y, Sakamoto H, Ishikawa S, Akagi K and Aburatani H:
Identification of chromosomal aberrations of metastatic potential
in colorectal carcinoma. Genes Chromosomes Cancer. 49:487–496.
2010.PubMed/NCBI
|
|
14
|
Yau C and Holmes CC: CNV discovery using
SNP genotyping arrays. Cytogenet Genome Res. 123:307–312. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Phillips JL, Hayward SW, Wang Y, Vasselli
J, Pavlovich C, Padilla-Nash H, Pezullo JR, Ghadimi BM, Grossfeld
GD, Rivera A, et al: The consequences of chromosomal aneuploidy on
gene expression profiles in a cell line model for prostate
carcinogenesis. Cancer Res. 61:8143–8149. 2001.PubMed/NCBI
|
|
16
|
Hyman E, Kauraniemi P, Hautaniemi S, Wolf
M, Mousses S, Rozenblum E, Ringnér M, Sauter G, Monni O, Elkahloun
A, et al: Impact of DNA amplification on gene expression patterns
in breast cancer. Cancer Res. 62:6240–6245. 2002.PubMed/NCBI
|
|
17
|
Pollack JR, Sørlie T, Perou CM, Rees CA,
Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Børresen-Dale AL
and Brown PO: Microarray analysis reveals a major direct role of
DNA copy number alteration in the transcriptional program of human
breast tumors. Proc Natl Acad Sci USA. 99:12963–12968. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsafrir D, Bacolod M, Selvanayagam Z,
Tsafrir I, Shia J, Zeng Z, Liu H, Krier C, Stengel RF, Barany F, et
al: Relationship of gene expression and chromosomal abnormalities
in colorectal cancer. Cancer Res. 66:2129–2137. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ramakrishna M, Williams LH, Boyle SE,
Bearfoot JL, Sridhar A, Speed TP, Gorringe KL and Campbell IG:
Identification of candidate growth promoting genes in ovarian
cancer through integrated copy number and expression analysis. PLoS
One. 5:e99832010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nigro JM, Misra A, Zhang L, Smirnov I,
Colman H, Griffin C, Ozburn N, Chen M, Pan E, Koul D, et al:
Integrated array-comparative genomic hybridization and expression
array profiles identify clinically relevant molecular subtypes of
glioblastoma. Cancer Res. 65:1678–1686. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cardoso J, Boer J, Morreau H and Fodde R:
Expression and genomic profiling of colorectal cancer. Biochim
Biophys Acta. 1775:103–137. 2007.
|
|
22
|
Yoshida T, Kobayashi T, Itoda M, Muto T,
Miyaguchi K, Mogushi K, Shoji S, Shimokawa K, Iida S, Uetake H, et
al: Clinical omics analysis of colorectal cancer incorporating copy
number aberrations and gene expression data. Cancer Inform.
9:147–161. 2010.PubMed/NCBI
|
|
23
|
Pedrocchi M, Schäfer BW, Mueller H,
Eppenberger U and Heizmann CW: Expression of Ca(2+)-binding
proteins of the S100 family in malignant human breast-cancer cell
lines and biopsy samples. Int J Cancer. 57:684–690. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Böni R, Heizmann CW, Doguoglu A, Ilg EC,
Schäfer BW, Dummer R and Burg G: Ca(2+)-binding proteins S100A6 and
S100B in primary cutaneous melanoma. J Cutan Pathol. 24:76–80.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lauriola L, Michetti F, Maggiano N, Galli
J, Cadoni G, Schäfer BW, Heizmann CW and Ranelletti FO: Prognostic
significance of the Ca(2+) binding protein S100A2 in laryngeal
squamous-cell carcinoma. Int J Cancer. 89:345–349. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Feng G, Xu X, Youssef EM and Lotan R:
Diminished expression of S100A2, a putative tumor suppressor, at
early stage of human lung carcinogenesis. Cancer Res. 61:7999–8004.
2001.PubMed/NCBI
|
|
27
|
Gupta S, Hussain T, MacLennan GT, Fu P,
Patel J and Mukhtar H: Differential expression of S100A2 and S100A4
during progression of human prostate adenocarcinoma. J Clin Oncol.
21:106–112. 2003. View Article : Google Scholar
|
|
28
|
Tsai ST, Jin YT, Tsai WC, Wang ST, Lin YC,
Chang MT and Wu LW: S100A2, a potential marker for early recurrence
in early-stage oral cancer. Oral Oncol. 41:349–357. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Simonsen K, Rode A, Nicoll A, Villadsen G,
Espelund U, Lim L, Angus P, Arachchi N, Vilstrup H, Nexo E, et al:
Vitamin B12 and its binding proteins in hepatocellular carcinoma
and chronic liver diseases. Scand J Gastroenterol. 49:1096–1102.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Salama I, Malone PS, Mihaimeed F and Jones
JL: A review of the S100 proteins in cancer. Eur J Surg Oncol.
34:357–364. 2008. View Article : Google Scholar
|
|
31
|
Haase-Kohn C, Wolf S, Lenk J and Pietzsch
J: Copper-mediated cross-linking of S100A4, but not of S100A2,
results in proinflammatory effects in melanoma cells. Biochem
Biophys Res Commun. 413:494–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jamieson NB, Carter CR, McKay CJ and Oien
KA: Tissue biomarkers for prognosis in pancreatic ductal
adenocarcinoma: a systematic review and meta-analysis. Clin Cancer
Res. 17:3316–3331. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
McKiernan E, McDermott EW, Evoy D, Crown J
and Duffy MJ: The role of S100 genes in breast cancer progression.
Tumour Biol. 32:441–450. 2011. View Article : Google Scholar
|
|
34
|
Jin L, Shen Q, Ding S, Jiang W, Jiang L
and Zhu X: Immunohistochemical expression of Annexin A2 and S100A
proteins in patients with bulky stage IB-IIA cervical cancer
treated with neoadjuvant chemotherapy. Gynecol Oncol. 126:140–146.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wolf S, Haase-Kohn C and Pietzsch J:
S100A2 in cancero-genesis: A friend or a foe? Amino Acids.
41:849–861. 2011. View Article : Google Scholar
|
|
36
|
Ranganathan P, Agrawal A, Bhushan R,
Chavalmane AK, Kalathur RK, Takahashi T and Kondaiah P: Expression
profiling of genes regulated by TGF-beta: Differential regulation
in normal and tumour cells. BMC Genomics. 8:982007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Naz S, Ranganathan P, Bodapati P, Shastry
AH, Mishra LN and Kondaiah P: Regulation of S100A2 expression by
TGF-β-induced MEK/ERK signalling and its role in cell
migration/invasion. Biochem J. 447:81–91. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Giráldez MD, Lozano JJ, Cuatrecasas M,
Alonso-Espinaco V, Maurel J, Mármol M, Hörndler C, Ortego J, Alonso
V, Escudero P, et al: Gene-expression signature of tumor recurrence
in patients with stage II and III colon cancer treated with
5-fluoruracil-based adjuvant chemotherapy. Int J Cancer.
132:1090–1097. 2013. View Article : Google Scholar
|
|
39
|
Haller DG, Tabernero J, Maroun J, de Braud
F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K and
Schmoll HJ: Capecitabine plus oxaliplatin compared with
fluorouracil and folinic acid as adjuvant therapy for stage III
colon cancer. J Clin Oncol. 29:1465–1471. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gao P, Song YX, Wang ZN, Xu YY, Tong LL,
Sun JX, Yu M and Xu HM: Is the prediction of prognosis not improved
by the seventh edition of the TNM classification for colorectal
cancer? Analysis of the surveillance, epidemiology, and end results
(SEER) database. BMC Cancer. 13:1232013. View Article : Google Scholar : PubMed/NCBI
|
